153
Participants
Start Date
February 27, 2017
Primary Completion Date
April 16, 2019
Study Completion Date
April 16, 2019
JHL1101
1000 mg containing 10 mg/mL rituximab to be diluted to a concentration of 1 to 4 mg/mL in 0.9% normal saline or 5% D-glucose for administration
MabThera
1000 mg containing 10 mg/mL rituximab to be diluted to a concentration of 1 to 4 mg/mL in 0.9% normal saline or 5% D-glucose for administration
JHL Biotech Investigational Site, Taipei
JHL Biotech Investigational Site, Taichung
JHL Biotech Investigational Site, Budapest
JHL Biotech Investigational Site, Sofia
JHL Biotech Investigational Site, Sofia
JHL Biotech Investigational Site, Plovdiv
JHL Biotech Investigational Site, Taipei
JHL Biotech Investigational Site, Prague
JHL Biotech Investigational Site, Bad Doberan
JHL Biotech Investigational Site, Vinnytsia
JHL Biotech Investigational Site, Rendsburg
JHL Biotech Investigational Site, Hildesheim
JHL Biotech Investigational Site, Poltava
JHL Biotech Investigational Site, Magdeburg
JHL Biotech Investigational Site, Kharkiv
JHL Biotech Investigational Site, Bijeljina
JHL Biotech Investigational Site, Banja Luka
JHL Biotech Investigational Site, Lviv
JHL Biotech Investigational Site, Moscow
JHL Biotech Investigational Site, Moscow
JHL Biotech Investigational Site, Yaroslavl
JHL Biotech Investigational Site, Saint Petersburg
JHL Biotech Investigational Site, Saint Petersburg
JHL Biotech Investigational Site, Saratov
JHL Biotech Investigational Site, Kazan'
JHL Biotech Investigational Site, Samara
JHL Biotech Investigational Site, Vilnius
JHL Biotech Investigational Site, Poznan
JHL Biotech Investigational Site, Wroclaw
JHL Biotech Investigational Site, Kyiv
JHL Biotech Investigational Site, London
JHL Biotech Investigational Site, Southampton
Lead Sponsor
JHL Biotech, Inc.
INDUSTRY